Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment.

Autor: Tervonen T; Kielo Research, Zug, Switzerland., Whichello C; Evidera Inc., London, UK., Law E; Pfizer Inc., New York City, New York, USA., Mauer J; Pfizer Inc., New York City, New York, USA., Mitra D; Pfizer Inc., New York City, New York, USA., Trapali M; Evidera Inc., London, UK., Krucien N; Evidera Inc., London, UK., Hauber B; Pfizer Inc., New York City, New York, USA.
Jazyk: angličtina
Zdroj: The Journal of dermatology [J Dermatol] 2024 Feb; Vol. 51 (2), pp. 243-252. Date of Electronic Publication: 2023 Dec 12.
DOI: 10.1111/1346-8138.17056
Abstrakt: PRODUCTS with janus kinase (JAK) inhibition have been shown to promote hair regrowth in patients with alopecia areata (AA). To guide drug-approval and treatment decisions, it is important to understand patients' willingness to accept the potential risks of JAK inhibition in exchange for potential benefits. We quantified the treatment preferences of adult (≥18 years) and adolescent patients (12-17 years) with AA in the US and Europe to determine the trade-offs they are willing to make between benefits and risks. Preferences for oral AA treatment attributes were elicited using a discrete choice experiment consisting of 12 tasks in which patients chose between two hypothetical treatment alternatives and no treatment. Benefits included the probability of 80%-100% scalp hair regrowth (Severity of Alopecia Tool score ≤ 20) and achieving moderate-to-normal eyebrow and eyelash hair. Treatment-related risks included 3-year probabilities of serious infection, cancer, and blood clots. Preference estimates were used to calculate the maximum level of each risk that patients were willing to accept for increases in treatment benefits. The most important attribute to both adults (n = 201) and adolescents (n = 120) was a 50% probability of achieving hair regrowth on most or all the scalp; however, adolescents placed greater relative importance on this attribute than did adults. Adults were averse to the risks of serious infection, cancer, and blood clots, whereas adolescents were averse to the risk of cancer. For a 20% increase in the probability of 80%-100% scalp hair regrowth, adults were willing to accept a mean (95% confidence interval) 3-year risk of serious infection, cancer, and blood clots of 7.4% (5.5-9.3), 2.5% (1.9-3.1), and 9.3% (6.4-12.2). Adolescents were willing to accept a 3-year risk of cancer of 3.3% (2.4-4.2). Patients with AA in the US and Europe are willing to accept substantial risks to obtain an effective treatment.
(© 2023 Japanese Dermatological Association.)
Databáze: MEDLINE
Externí odkaz: